Psoriasis is a common chronic inflammatory skin disorder characterized by sharply demarcated red scaly plaques, which may occur on any part of the body but preferentially at extensor areas. The prevalence is about 2% to 3% of the adult population and affects men and women equally and can be seen in all races.1,2 Psoriasis has grave impacts on the quality of life, even in patients with a mild disease. 3 Researchers believe the disease is caused by genetic and environmental factors and is an autoimmune disease.4 The pathophysiology of psoriasis is characterized by an increase in antigen presentation, T-cell activation, and T-helper cell type 1 cytokines. Also, an increasing level of C-reactive protein levels and platelet activation factors has been observed.45 Heredity undoubtedly plays a role in causing psoriasis, and several psoriatic human genes have been identified. However, environmental factors also play a role in the etiology of this disease.46 These factors include trauma, endocrine and metabolic factors, drugs, smoking, alcohol, sunlight, and some infections.2, 4 The role of infectious agents Streptococci A has been demonstrated.6 Recent studies have shown that H pylori may also, like the Streptococcus hemolytic group A, be a trigger factor in psoriasis,7-10 although some other studies have refuted this relationship.11,12 H pylori is a Gram-negative micro-aerophilic spiral bacterium that resides in the gastric mucosa and plays a role in the pathogenesis of gastritis and peptic ulceration.13,14 Recent evidence suggests that H pylori infection plays roles in the pathogenesis of various skin diseases.15,16 The prevalence of H pylori infection is 30% in the United States and other developed countries and is over...
The infection is acquired by oral ingestion of the bacterium and is mainly transmitted within families in the early childhood. Several methods are available for the detection of *H. pylori* infection. Serology investigation is specific in more than 90% of the cases. *H. pylori* infection produces IgG and IgM against *H. pylori*; IgM increases in the serum in acute infections and IgG increases in chronic infections. The ELISA method can be used to determine the level of antibodies especially for epidemiological studies, for the detection of infection in individuals. *H. pylori* infection develops gastrointestinal diseases and has recently been shown to develop extraintestinal diseases. Although psoriasis is not a life-threatening disease, and for those who are not suffering from it may not seem important, it can affect the quality of life of affected individuals. Due to the conflicting results regarding the relationship between psoriasis and *H. pylori*, the aim of this study was to evaluate the relationship between the two.

**METHODS**

This case-control study was done on 61 patients with psoriasis vulgaris (cases) and 61 healthy individuals (controls) in Fatemiyeh Hospital (referral center for the treatment of skin diseases), Semnan, Iran, during April 2011 to April 2012. Before starting, the study was approved by the ethics committee of Semnan University of Medical Sciences, Iran. Otherwise healthy individuals that had visited the dermatologist for cosmetic problems (control group) and documented psoriasis vulgaris patients (case group) fulfilled the inclusion criteria. Patients with a history of gastrointestinal problem, those who used oral corticosteroid or β-Blockers, and who used topical and systemic medication for 2 and 6 months, respectively, were excluded. All patients submitted their voluntarily written consent for the study. On the first visit, all patients were examined by a dermatologist; then, checklists that included information about age, sex, medical history, and drug history were completed. Psoriatic patients were clinically assessed before treatment on the basis of the psoriasis area and severity index (PASI) score and percentage of body surface area involved. The PASI was used to determine the severity of skin disease. The effect of IgG against *H. pylori* was examined in all patients using enzyme-linked immunosorbent assay (ELISA) kit (DRG Instruments, GmbH, Marburg, Germany) according to the manufacturer’s protocol. The statistical analysis of the results was performed using paired student *t*-Chi-square, and logistic regression tests in SPSS, version 18 for windows. In this study, the significance level was set at *P* values of equal and less than .05.

**RESULTS**

About 33 (54%) of psoriasis patients and 37 (60%) of the controls were female. Both groups were matched for sex (*P*=.464). In psoriasis patients, the age ranged from 9 to 61 years with a mean (SD) 33.3 (13.7) years and in the control group, the age ranged from 17 to 60 years with a mean (SD) 28/3 (8.4) years; the difference was significant (*P*=.017). The mean (SD) number of years that have passed since the development of psoriasis in 61 patients was 9.8 (8.3) years, with a median of 8 years. The PASI score range was 2.7 to 16.8 in patients with a mean (SD) 6.6 (3.1). The mean (SD) serum IgG in psoriasis patients was 17.3 (10.1) IU/ML and in the control group, 16.1 (10) IU/ML. Distribution levels were not significantly different between the two groups (*P*=.302) (Figure 1). Due to the lack of homogeneity between the 2 groups in terms of age, the logistic revealed that there were significant differences (*P*=.001, CI=0.41-1.42) (Figure 2). Regression analysis to examine the relationship between PASI score and serum IgG showed no significant correlation (*P*=.39) (Figure 3).

**DISCUSSION**

The relationship between psoriasis and *H. pylori* is a challengeable issue in dermatology and gastroenterology. Our study reported no significant relationship between anti-*H. pylori* serum IgG levels and psoriasis. Also no significant differences were found between psoriasis severity and IgG levels against *H. pylori*. However, we found a significant relationship between the duration of psoriasis and serum IgG anti-*H. pylori* levels. Fabrizi et al. in Italy (in 2007) showed that 10% of people with psoriasis and 17% of the control group have *H. pylori* infection. This study result is compatible with our study. In a study by Wedi and Kapp in Germany (in 2002), no relationship between psoriasis and *H. pylori* was seen. Additional studies are contrary to the results of this study; for example, in a study by Qayoom and Ahmad in India (in 2003), the incidence of *H. pylori* infection in psoriatic patients was 44%, while in the control group it was only 10%. Also Halasz CL in 1996 showed that the prevalence of IgG against *H. pylori* was in 54% of psoriatic patients, but this study had no control group for comparison. In a study by Onsun et al. in 2012, 300 patients with psoriasis and 150 healthy individuals were enrolled. The PASI score in patients infected with *H. pylori* was clearly higher, and simultaneous treatment of psoriasis and *H. pylori* in patients with psoriasis was more effective than psoriasis treatment alone. In contrast to our study, they suggested that *H. pylori* infection plays a role in psoriasis severity, and *H. pylori* infection.
pylori treatment was effective in the treatment of psoriasis. In our study, the only significant relationship was seen between the duration of psoriasis and the serum IgG level against *H. pylori*. This may be due to the use of topical or systemic immunosuppressive drugs over time that gave psoriatic patients greater susceptibility to *H. pylori* infection. Today, the existing controversy about the relationship between psoriasis and *H. pylori* infection is perhaps due to difference in sample sizes, severity of disease, and difference in the level of public health. So it appears that the relationship between psoriasis and *H. pylori* infection is not clear. Finally more researches need to be done to clarify this issue.
brief report

REFERENCES

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004; 9(2):136-9.

2. Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26(4):314-20.

3. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41(3 Pt 1):401-7.

4. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361(5):496-509.

5. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 Suppl 2:i30-6.

6. Griffiths CEM, Camp R, D., R, Barker, J. N. W. N. Psoriasis. In: T. Burns SB, N. Cox and C. Griffiths, editor. Roos’ Textbook of Dermatology. Malden, Massachusetts, USA: Blackwell Publishing, Inc; 2008.

7. Qayoom S, Ahmad QM. Psoriasis and Helicobacter Pylori. Indian J Dermatol Venereol Leprol 2003; 69(2):130-4.

8. Halasz CL. Helicobacter pylori antibodies in patients with psoriasis. Arch Dermatol 1996; 132(1):95-6.

9. Onsun N, Arda Ulusal H, Su O, Beycan I, Biyik Ozkaya D, Senocak M. Impact of Helicobacter Pylori infection on severity of psoriasis and response to treatment. Eur J Dermatol 2012; 22(1):117-20.

10. Ali M, Whitehead M. Clearance of chronic psoriasis after eradication therapy for Helicobacter pylori infection. J Eur Acad Dermatol Venereol 2008; 22(6):753-5.

11. Fadri G, Carbone A, Lippi ME, Anti M, Gasbarrini G. Lack of evidence of relationship between Helicobacter pylori infection and psoriasis in childhood. Arch Dermatol 2001; 137(11):1529.

12. Wedi B, Kapp A. Helicobacter pylori infection in skin diseases: a critical appraisal. Am J Clin Dermatol 2002; 3(4):273-82.

13. Peek RM, Jr., Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2(1):29-37.

14. Sibony M, Jones NL. Recent advances in Helicobacter pylori pathogenesis. Curr Opin Gastroenterol 2012; 28(1):30-5.

15. Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatologic diseases. Eur J Dermatol 2009; 19(5):431-44.

16. Moravej H, Hoseini H, Barikbin B, Malekzadeh R, Razavi G. Relationship of Helicobacter pylori with lichen planus. Indian Journal of Dermatology Venereology 2007; 52(3):138.

17. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut. 1994; 35(8):742-5.

18. Rowland M, Kumar D, Daly L, O’Connor P, Vaughan D, Drumm B. Low rates of Helicobacter pylori reinfection in children. Gastroenterology 1999; 117(2):336-41.

19. Suarez S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347(15):1175-86.

20. Scorek BL, Kelley PW, Taylor DN. Seroprevalence of Helicobacter pylori infections in a cohort of US Army recruits. Am J Epidemiol 1994; 139(5):513-9.

21. Parsonnet J, Isaacscon PG. Bacterial infection and MALT lymphoma. N Engl J Med 2004; 350(3):213-5.